|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1175 USD | -1.26% |
|
+0.34% | +657.96% |
| 06-25 | Sunshine Biopharma Secures Approval for Generic Anastrozole in Canada | MT |
| 06-01 | Sunshine Biopharma Says Rivaroxaban Received Canadian Approval | MT |
| Market Cap | 2.93M 2.56M 2.38M 2.19M 4.12M 282M 4.18M 28.35M 11.1M 138M 10.98M 10.75M 477M | P/E 2026 * |
-0.29x | P/E 2027 * | 9.05x |
|---|---|---|---|---|---|
| Enterprise Value | 2.93M 2.56M 2.38M 2.19M 4.12M 282M 4.18M 28.35M 11.1M 138M 10.98M 10.75M 477M | EV / Sales 2026 * |
0.08x | EV / Sales 2027 * | 0.07x |
| Free-Float |
88.48% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.26% |
| Manager | Title | Age | Since |
|---|---|---|---|
Steve Slilaty
CEO | Chief Executive Officer | 74 | 2009-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 65 | 2009-10-14 |
Michel Roy
PRN | Corporate Officer/Principal | 58 | 2025-01-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Steve Slilaty
CHM | Chairman | 74 | 2009-10-14 |
Camille Sebaaly
BRD | Director/Board Member | 65 | 2025-12-10 |
Rabi Kiderchah
BRD | Director/Board Member | 53 | 2021-10-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.26% | +0.34% | - | - | 2.93M | |
| +0.48% | -0.72% | +45.30% | +152.71% | 1,037B | |
| -0.20% | +2.22% | +51.10% | +49.35% | 615B | |
| +0.39% | +0.28% | +33.88% | +78.17% | 448B | |
| +4.09% | +3.92% | +31.88% | +26.00% | 326B | |
| -0.37% | +1.25% | +34.02% | +37.44% | 293B | |
| -1.34% | -0.76% | +17.41% | +16.25% | 264B | |
| +0.01% | -4.60% | -27.65% | -41.75% | 216B | |
| -0.91% | -2.59% | +17.06% | +53.75% | 198B | |
| -1.70% | -6.10% | +12.70% | +64.80% | 162B | |
| Average | -0.10% | +1.12% | +23.97% | +48.53% | 395.27B | |
| Weighted average by Cap. | +0.24% | +1.47% | +33.17% | +72.96% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 35.39M 31.01M 28.79M 26.45M 49.84M 3.41B 50.58M 343M 134M 1.67B 133M 130M 5.77B | 45M 39.43M 36.6M 33.64M 63.38M 4.34B 64.31M 436M 171M 2.12B 169M 165M 7.34B |
| Net income | -3.15M -2.76M -2.56M -2.35M -4.43M -304M -4.5M -30.5M -11.94M -149M -11.82M -11.56M -513M | 102K 89.81K 83.38K 76.61K 144K 9.89M 146K 993K 389K 4.84M 385K 376K 16.72M |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.810USD
Average target price
56.00USD
Spread / Average Target
+2,993.92%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SBFM Stock
- SBFM Stock
Select your edition
All financial news and data tailored to specific country editions
